Primary prevention of CVD to high risk PAD patients, a Sprectrum of Risk: role of lipid lowering and antiplatelet therapy

Beth L. Abramson MD MSc FRCP FACC

Paul Albrechtsen Professor in Cardiac Prevention & Women's CV Health Associate Professor of Medicine, U. of Toronto Division of Cardiology, St. Michael 's Hospital



e cardiologie



Presenter Disclosure

Dr. Beth Abramson

Primary Prevention of CVD to High-Risk Patients: Role of lipid lowering and antiplatelet therapy

Relationships with financial sponsors:

- Grants/Research Support: N/A
- Speakers Bureau/Honoraria: Amgen, AstraZeneca, Bayer, BioSyent, BMS-Pfizer, Boehringer-Ingelheim, CHRC, CPD Network Association, HLS Therapeutics, Novartis, Novo Nordisk, Sanofi, Servier
- Consulting Fees: Canadian Cardiovascular Society (Co-Chair of Guidelines and Speaker)
- Patents: N/A
- **Other:** Support for Cardiometabolic Clinic at St. Michael's Hospital Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, HLS Therapeutics, Novartis, Novo Nordisk; Sponsored a Prevention Fellowship - Janssen

Overall learning objectives

Participants should be able to:

- 1. Review lipid lowering and risk enhancers in primary prevention
- 2. Review lipid lowering in higher risk PAD patients
- 3. Review the role of ASA in primary prevention
- 4. Review evidence based medical therapy for antithrombotic therapy in PAD



Polling Question 1:

- In a 65 year old with DM, MI 18 month ago, with EGFR of 49, optimal anticoagulation is:
- EC ASA 81
- DAPT
- EC ASA 81 + Rivaroxiban 2.5 BID
- EC ASA 81 + Rivaroxiban 5 BID
- None of the above




Polling Question 2:

- In a 49 year old with PAD optimal anticoagulation is:
- EC ASA 81
- DAPT
- EC ASA 81 + Rivaroxiban 2.5 BID
- EC ASA 81 + Rivaroxiban 5 BID
- None of the above




Update on Cardiac Prevention trials 2004 -Being aggressive outside of the Cath Lab


Beth L. Abramson, MD, FRCPC FACC Director: Cardiac Prevention & Rehabilitation Centre & Women's Cardiovascular Health St. Michael's Hospital, Division of Cardiology Assistant Professor of Medicine, University of Toronto



Atherosclerosis is a DIFFUSE ARTERIAL PROCESS




RESIDUAL RISK PATHWAYS IN SECONDARY PREVENTION



Current concepts of residual risk

Treatment Approach for Primary Prevention Patients (Without a Statin Indicated Condition)[‡]



carcium, AO, Agaiston unit, RX, prescription, DAS, bie acid sequestiant. From, https://doi.org/10.1010/j.jca.2021.03.016, Peasonet al. 2021 Canadian Cardiovascular Society Guidelines for the Management of Dy

Low-Risk* FRS <10%

Statin Indicated Conditions:

Statin therapy not recommended for most low risk individuals; exceptions include: (a) LDL-C \geq 5.0 mmol/L (or ApoB \geq 1.45 q/L or non-HDL-C \geq 5.8 mmol/L) – see Figure 2; or (b) FRS is 5%-9.9% with LDL-C \geq 3.5 mmol/L (or non-HDL-C \geq 4.2 mmol/L or ApoB \geq 1.05 g/L), particularly with other CV risk modifiers (e.g., FHx, $Lp(a) \ge 50 \text{ mg/dL}$ [or ≥ 100 nmol/L] or CAC >0 AU) as the proportional benefit from statin therapy may be similar to other treated groups.

• LDL <u>></u> 5

- Framingham 5-9.9%:
- LDL <u>></u> 3.5 (non HDL <u>></u>4.2 or Apo B <u>></u>1.05
- Lpa > 100 nml.L
- CAC > 0



2021 CCS Recommendations for Lp(a) as a Biomarker for Improving Risk Stratification and Dyslipidemia Management

Measuring Lp(a) level **ONCE** in a person's lifetime as a part of the initial lipid screening is recommended

(Strong Recommendation; High Quality Evidence)


For all patients in the setting of primary prevention with an Lp(a) ≥50 mg/dL (or ≥100 nmol/L), earlier and more intensive health behaviour modification counselling and management of other ASCVD risk factors is recommended

(Strong recommendation; Expert consensus)

https://www.lpaclinicalguidance.com/


https://www.lpaclinicalguidance.com/

Your risk of having a heart attack or stroke



Your risk of having a heart attack or stroke up to age 80 is:

With an Lp(a) level of 180 nmol/L, your estimated risk of having a heart attack or stroke up to age 80 changes from 20.8% to:







SPECIAL ARTICLE Miscellaneous

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement

Graphical Abstract



Lifetime risk of major cardiovascular events with higher lifetime exposure to Lp(a) and lower lifetime exposure to LDL-C




Intensification of LDL-C reduction needed to reduce the global cardiovascular risk to a similar extent as the risk attributable to elevated Lp(a) depending on age at which LDL-C reduction is initiated Intensification of LDL-C reduction (nmol/L) needed to mitigate the increased risk caused by Lp(a)

Lp(a) nmol/L	Δ Lp(a) compared to median	Lp(a) percentile	HR for MCVE due to increased Lp(a)	Begin age 30y	Begin age 40y	Begin age 50y	Begin age 60y
320	300	99	2.56	1.2 mmol/L	1.4 mmol/L	1.7 mmol/L	2.3 mmol/L
270	250	97.5	2.19	1.0 mmol/L	1.2 mmol/L	1.5 mmol/L	1.9 mmol/L
220	200	93.5	1.87	0.8 mmol/L	0.9 mmol/L	1.2 mmol/L	1.5 mmol/L
170	150	90	1.60	0.6 mmol/L	0.7 mmol/L	0.9 mmol/L	1.1 mmol/L
120	100	82.5	1.37	0.4 mmol/L	0.5 mmol/L	0.6 mmol/L	0.8 mmol/L
70	50	75	1.17	0.2 mmol/L	0.2 mmol/L	0.3 mmol/L	0.4 mmol/L
20	ref.	50	ref.	ref.	ref.	ref.	ref.


Kronenberg F et al. Eur Heart J 2022;43:3925-46

New Areas of Focus in Primary Prevention



Lack of CV benefit of omega-3 fatty acids from dietary sources or other formulations/supplements

Atherosclerosis is a systemic disease that can affect multiple arterial beds



Cerebrovascular disease

Coronary artery disease

- Peripheral arterial disease

- Intermittent claudication
- Critical limb ischemia




In the Fast Paced World of Cardiology...






PAD is the Poor Cousin!







But it's Just as Deadly!



CCS 2022 Guidelines for PAD

Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease

Beth L. Abramson, MD (Co-Chair), Mohammed Al-Omran, MD (Co-Chair), Sonia S. Anand, MD (Co-Chair), Zaina Albalawi, MD, Thais Coutinho, MD, Charles de Mestral, MDCM, PhD, Luc Dubois, MD, Heather L. Gill, MD, Elisa Greco, MD, Randolph Guzman, MD, Christine Herman, MD, Mohamad A. Hussain, MD, PhD, Victor F. Huckell, MD, Prasad Jetty, MD, Eric Kaplovitch, MD, Erin Karlstedt, MD, Ahmed Kayssi, MD, Thomas Lindsay, MDCM, G.B John Mancini, MD, Graham McClure, MD, M. Sean McMurtry, MD, PhD, Hassan Mir, MD, Sudhir Nagpal, MD, Patrice Nault, MD, Thang Nguyen, MD, Paul Petrasek, MD, Luke Rannelli, MD, Derek J. Roberts, MD, PhD, Andre Roussin, MD, Jacqueline Saw, MD, Kajenny Srivaratharajah, MD, James Stone, MD, PhD, David Szalay, MD, Darryl Wan, MD, Heather Cox, MD, Subodh Verma, MD, Sean Virani, MD

> Canadian Journal of Cardiology Volume 38 Issue 5 Pages 560-587 (May 2022) DOI: 10.1016/j.cjca.2022.02.029

Over the past 2 decades there have been substantial advances in diagnostics, pharmacotherapy, and interventions to aid in the management of PAD patients


To summarize the evidence regarding approaches to diagnosis, risk stratification, medical and intervention treatments for patients with PAD, guided by the GRADE framework, evidence was synthesized, and assessed for quality

Fifty-six recommendations were made





Société canadienne de cardiologie The presence of polyvascular disease is the most potent risk factor for future cardiovascular events



Risk of cardiovascular event (cardiovascular death/MI/stroke) in patients with disease in multiple vascular beds (Taken from secondary data analysis of EUCLID trial)

PAD = peripheral arterial disease; CeVD = cerebrovascular disease; CAD = coronary artery disease



Lipid-lowering and PAD

We recommend that patients with PAD qualify as statin-indicated patients and should receive lipid-modifying therapy for the reduction of death, CV death, nonfatal MI, nonfatal stroke (MACE), and MALE concordant with the recommendations in the 2021 Canadian Cardiovascular Society (CCS) guidelines for the management of dyslipidemia (*Strong Recommendation; High-Quality Evidence*).


a. Maximally tolerated dose of statin therapy

b. Statin add-on therapies (ezetimibe and/or PCSK-9 inhibitors) if receiving maximally tolerated dose of statin therapy and the low-density lipoprotein cholesterol is 1.8 mmol/L, non-high-density lipoprotein cholesterol 2.4 mmol/L or apolipoprotein B100 0.7 mg/dL.

We recommend that patients with PAD, who, despite maximally tolerated dose of statin therapy have a triglyceride level of 1.5-5.6 mmol/L, should be considered for use of icosapent ethyl for the reduction CV death, nonfatal MI, and nonfatal stroke concordant with the recommendations in the 2021 CCS guidelines for the management of dyslipidemia (Strong Recommendation; Moderate-Quality Evidence).




Peripheral Artery Disease and Risk in Placebo Patients



350.

ted age, sex, race, BMI, diabetes, nypertension, smoking, eGFR, CHF, prior i CABG/PCI, and history of stroke or TIA.

CV Death, MI or Stroke in Patients with fourier and without Peripheral Artery Disease




Circulation. 2018;137:338–350.

MACE or MALE



In Patients with and without PAD



Circulation. 2018;137:338–350.





- Patients with PAD are at heightened risk of MACE and MALE
- LDL-C lowering with evolocumab in patients with PAD:
 - Reduces major adverse CV events with robust ARR
 - Reduces major adverse limb events
- Benefits extend to PAD without prior MI or stroke with an ARR for MACE or MALE of 6.3% (NNT 16) at 2.5 years

Circulation. 2018;137:338–350.



ASA in PRIMARY PREVENTION




Gaziano et al. Lancet. 2018 Aug. <u>//doi.org/10.1016/S0140-6736(18)31924-X</u> McNeil JJ, et al. NEJM. 2018;379(16):1509-1518. Zheng SL, et al. JAMA. 2019;321(3):277-287.

ACC/AHA CLINICAL PRACTICE GUIDELINE

2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease

A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

4.6. Aspirin Use



Circulation. September 10, 2019



Aspirin for Primary Prevention of CVD





An Asprin a day will help prevent a heart attack if you have it for lunch instead of a cheeseburger

COMPASS TRIAL: STUDY DESIGN

Assessing DOAC* in stable CAD

Mean follow-up 23 months – stopped for superiority

Rivaroxaban (2.5 mg BID) + ASA (100 mg QD)

27,395 PATIENTS Atherosclerotic vascular disease

Rivaroxaban (5 mg BID)

ASA (100 mg once daily)

Primary efficacy outcome: Composite of cardiovascular death, stroke or MI Primary safety outcome: Modified ISTH major bleeding

*In this program, the term DOAC (direct oral anticoagulant) is used, recognizing that it is interchangeable with the term NOAC (non-vitamin K oral anticoagulant) ASA, acetylsalicylic acid; BID, twice daily; CAD, coronary artery disease; DOAC, direct oral anticoagulant; ISTH, International Society on Thrombosis and Haemostasis; MI, myocardial infarction; NOAC, non-vitamin K oral anticoagulant; QD, once daily Eikelboom JW *et al.* N Engl J Med 2017; 377:1319-30.

STUDY DETAILS

PRIMARY EFFICACY ENDPOINTS

Composite of MI, stroke or cardiovascular death

KEY INCLUSION CRITERIA

- Meet criteria for CAD or PAD
- Patients with CAD must also meet at least one of the following:

■ Age ≥ 65 years OR

• Age < 65 years plus atherosclerosis in ≥ 2 vascular beds or ≥ 2 additional risk factors

Criteria for CAD:

Previous MI

History of angina

PCI

CABG

- Criteria for PAD:
 - Claudication with objective evidence of arterial disease
 - Previous amputation or revascularization
 - Previous carotid revascularization
 - Asymptomatic carotid disease with > 50% stenosis

PRIMARY SAFETY ENDPOINTS

Modified ISTH major bleeding*

KEY EXCLUSION CRITERIA

- High risk of bleeding
- Stroke ≤ 1 month or any hemorrhagic or lacunar stroke
- Severe HF with known ejection fraction < 30% or NYHA class III or IV symptoms
- eGFR < 15 mL/min
- Concomitant use of other anticoagulants
- · Chronic treatment with non-ASA antiplatelet therapy


*Primary safety outcome is a composite of:

- · Fatal bleeding and/or
- Symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular, retroperitoneal, intraarticular or pericardial, or intramuscular with compartment syndrome, or bleeding into the surgical site.

CABG: coronary artery bypass grafting; CAD: coronary artery disease; eGFR: estimated glomerular filtration rate; HF: heart failure; ISTH: International Society on Thrombosis and Haemostasis; MI: myocardial infarction; NYHA: New York Heart Association; PAD: peripheral artery disease; PCI: percutaneous coronary intervention. Bosch, J., et al. Accepted for publication in *Can J Cardiol* (2017).

COMPASS TRIAL: CV DEATH, STROKE, MI


Primary endpoint in the entire study population



Vascular dose rivaroxaban 2.5 mg BID + ASA significantly reduced composite primary endpoint of CV death, stroke or MI vs. ASA alone in patients with stable atherosclerotic vascular disease LU code 539

ASA, acetylsalicylic acid; BID, twice daily; CI, confidence interval; CV, cardiovascular; HR, hazard ratio; MI, myocardial infarction Eikelboom JW et al. N Engl J Med 2017; 377:1319-30.

COMPASS TRIAL: MAJOR BLEEDING RATES



ASA, acetylsalicylic acid; CI, confidence interval; HR, hazard ratio; ICH, intracerebral hemorrhage; ISTH, International Society on Thrombosis and Haemostasis Eikelboom JW *et al.* N Engl J Med 2017; 377:1319-30.

L.CA.MKT.06.2018.3774

Antithrombotic therapy

We recommend treatment with **rivaroxaban 2.5 mg twice daily in combination with aspirin (80-100 mg daily)** for management of patients with **symptomatic lower extremity PAD who are at high risk for ischemic events** (high-risk comorbidities such as polyvascular disease, diabetes, history of heart failure, or renal insufficiency and/or high-risk limb presentation post peripheral revascularization, limb amputation, rest pain, ischemic ulcers) and at low bleeding risk

(Strong Recommendation; High-Quality Evidence).

LU 539 in Ont.




We recommend combination treatment with rivaroxaban 2.5 mg twice daily and aspirin or single antiplatelet therapy for patients **with symptomatic lower extremity PAD and low bleeding risk in the absence of high-risk limb presentation or high-risk comorbidities** (*Strong Recommendation; High-Quality Evidence*).

We recommend **single antiplatelet therapy** with either aspirin (75-325 mg) or clopidogrel (75 mg) be considered for patients with symptomatic lower extremity PAD at **high bleeding risk** who remain eligible for antithrombotic therapy *(Strong Recommendation; High-Quality Evidence).*



SAVELIMB





Société canadienne de cardiologie Communauté. Connaissances. Leadership. Polling Question 1:

- In a 65 year old with DM, MI 18 month ago, with EGFR of 49, optimal anticoagulation is:
- EC ASA 81
- DAPT
- EC ASA 81 + Rivaroxiban 2.5 BID
- EC ASA 81 + Rivaroxiban 5 BID
- None of the above



Polling Question 2:

- In a 49 year old with PAD optimal anticoagulation is:
- EC ASA 81
- DAPT
- EC ASA 81 + Rivaroxiban 2.5 BID
- EC ASA 81 + Rivaroxiban 5 BID
- None of the above



